Specifically, the epigenetic profile of GABBR2 gene at promoter region prior to and following erlotinib treatment were compared in two IIIa stage NSCLC patients having EGFR activating mutations (exon19 p.E746-A750del and p.A750-E758del). This evidence concerns the gene GABBR2 and non-small cell lung carcinoma.